Aquestive Therapeutics Gets FDA Feedback on Anaphylm – Quick Resolution Expected

Aquestive Therapeutics receives FDA Complete Response Letter for Anaphylm with packaging-related deficiencies. Company plans rapid resolution and Q3 2026 resubmission.